Dexloxiglumide is primarily used in the field of gastroenterology as a selective antagonist for the cholecystokinin (CCK) receptor. It is particularly effective in managing gastrointestinal motility disorders by inhibiting the action of CCK, a hormone that plays a significant role in digestion and appetite regulation. This makes it a valuable therapeutic agent for conditions such as irritable bowel syndrome (IBS) and functional dyspepsia, where abnormal gut motility and sensitivity are key issues. Additionally, it has been explored for its potential in reducing symptoms of gastroesophageal reflux disease (GERD) by modulating gastric emptying and reducing acid secretion. Its targeted action on CCK receptors offers a more specific approach to treating these conditions with fewer systemic side effects compared to broader-acting medications.